Brief: Avenue Therapeutics Announces Agreement With The FDA On Phase 3 Study Design For IV Tramadol
25/07/2023 13:36
July 25 (Reuters) - Avenue Therapeutics Inc ATXI.O :
* AVENUE THERAPEUTICS ANNOUNCES AGREEMENT WITH THE FDA ON
THE
STUDY DESIGN AND ANALYSIS APPROACH OF THE PHASE 3 SAFETY STUDY
FOR IV TRAMADOL
* AVENUE THERAPEUTICS INC - IS SUBMITTING REVISED PROTOCOL
TO FDA
INCLUDING STATISTICAL PLAN FOR FINAL REVIEW
Source text for Eikon: ID:nGNX4dGljP
Further company coverage: ATXI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Avenue Therapeutics
See all newsBrief: Axsome Therapeutics Acquires AZD7325, A Selective GABA-A Modulator For Treatment Of Epilepsy
Avenue Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: Avenue Therapeutics Annji Intends To Terminate License Agreement With Co
Brief: Avenue Therapeutics Receives Delist Letter From Nasdaq Under Nasdaq Listing Rule 5550(B)(1)
Avenue Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary